← Back to Search

Monoclonal Antibodies

RMC-6291 + RMC-6236 for Advanced Solid Cancers

Q: Who meets the criteria to participate in this clinical evaluation?

<p>This trial necessitates that applicants have either non-<a href="https://www.withpower.com/clinical-trials/small-cell-lung-cancer">small cell lung cancer</a>, <a href="https://www.withpower.com/clinical-trials/colorectal-cancer">colorectal cancer</a>, pancreatic ductal adenocarcinoma or advanced solid tumors and be between 18 to 125 years old. A maximum of 210 patients can take part in this study.</p>

Phase 1

Recruiting

Research Sponsored by Revolution Medicines, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy

i. NSCLC, previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Study Summary

This trial tests if two new drugs are safe and effective to treat cancers with a specific gene mutation.

Who is the study for?

This trial is for adults with advanced solid tumors that have a specific mutation (KRAS G12C). Participants must have tried other treatments like immunotherapy and chemotherapy. They should be in good physical condition, but can't join if they've had recent surgery or active brain metastases.Check my eligibility

What is being tested?

The study tests the combination of two drugs, RMC-6291 and RMC-6236, on patients with KRAS G12C-mutated tumors to assess safety, how well the body tolerates them, and how the body processes these drugs.See study design

What are the potential side effects?

While not explicitly listed here, common side effects for cancer drug trials may include nausea, fatigue, liver issues, skin reactions and potential complications from lowered immune response.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer is advanced, cannot be cured with surgery, and has a specific KRAS mutation.

Select...

I have NSCLC and was treated with immunotherapy, chemotherapy, and KRAS G12C inhibitors.

Select...

I have NSCLC with small, symptom-free brain metastases and have had immunotherapy or chemotherapy.

Select...

I am fully active or can carry out light work.

Select...

My solid tumor has not been treated with KRAS G12C inhibitors.

Select...

I have NSCLC treated with immunotherapy and chemotherapy but not with KRAS G12C inhibitors.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Adverse events

Dose Limiting Toxicities

Secondary outcome measures

Area Under Blood Concentration Time Curve of RMC-6291 and RMC-6236

Disease Control Rate

Duration of Response (DOR)

+7 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: RMC-6291 and RMC-6236Experimental Treatment1 Intervention

Dose escalation and Dose expansion

0 / 7Eligibility criteria met

Find a Location

Who is running the clinical trial?

Revolution Medicines, Inc.Lead Sponsor

10 Previous Clinical Trials

1,852 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research trial available to individuals who are younger than 75?

"The enrollment parameters of this trial necessitate that participants must be no younger than 18 and not older than 125."

Answered by AI

What are the objectives of this study?

"Revolution Medicines, Inc. has outlined several primary and secondary endpoints to be measured over a three-year period for this clinical trial. The primary outcome is Dose Limiting Toxicities while the additional objectives are Overall Response Rate (ORR) as per RECIST v1.1 criteria, Duration of Response (DOR), and Disease Control Rate determined through RECIST v1.1 metrics."

Answered by AI

Who meets the criteria to participate in this clinical evaluation?

"This trial necessitates that applicants have either non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma or advanced solid tumors and be between 18 to 125 years old. A maximum of 210 patients can take part in this study."

Answered by AI

Have the FDA sanctioned RMC-6291 and RMC-6236 for public consumption?

"Since this is a Phase 1 trial, which implies limited data exists on the safety and effectiveness of RMC-6291 and RMC-6236, our team at Power rated their security as a score of one."

Answered by AI

Are there any openings to join this clinical trial currently available?

"As per the information provided on clinicaltrials.gov, this specific trial is not currently recruiting patients. It was initially put up for consideration in November of 2023 and has been revised since then; nevertheless, it does not have any open enrollment slots at present. Nevertheless, there are 2878 other medical studies that are still actively enrolling participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

2023. "Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06128551.

All > Colorectal Cancer Dallas